Skip to main content
SpringerLink
Log in

Steady state pharmacokinetics of piroxicam in children with rheumatic diseases

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Ten children with rheumatoid arthritis, aged 7–16 y and weighing 20–63 kg, were treated with piroxicam mean dose 0.4 mg·kg−1 once daily for 2 weeks. On Day 15, blood was sampled from 2–120 h after the last dose.

The Cmax for piroxicam ranged from 3.6 to 9.8 (mean 6.6) mg·l−1 and its half-life by log linear computation was 22 to 40 (mean 32.6) h. The volumes of distribution and the total body clearance were estimated as the ratio of actual volumes of distribution and actual clearances to availability. The volumes of distribution (V/F) were 0.12 to 0.25 (mean 0.16) l·kg−1, and the total body clearances (CL/F) were 2.1 to 5.0 (mean 3.4) ml·kg−1·−1.

Thus, piroxicam clearance in these patients was higher and its half-life was shorter than those previously reported in young adults, yet V appeared similar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Darragh A, Gordon AJ, O'Byrne H, Hobbs D, Casey E (1985) Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults. Eur J Clin Pharmacol 28: 305–309

    Google Scholar 

  • De Vere-Tyndall AG, Ansell BM (1980) Piroxicam in juvenile chronic arthritis: a pilot study. Dessain P (ed) Rheumatology in the 80's. An advance in therapy, piroxicam. Symposium Proceedings, Malaga, Excerpta Medica; 45–51

    Google Scholar 

  • Olkkola KT, Maunuksela E-L, Korpela R (1989) Pharmacokinetics of post-operative intravenous indomethacin in children. Pharmacol Toxicol 65: 157–160

    Google Scholar 

  • Richardson CJ, Ross SG, Blocka KL, Veerbeck RK (1986) High performance liquid chromatography analysis of piroxicam and its major metabolite 5′-hydroxypiroxicam in human plasma and urine. J Chromatogr 1986; 382: 382–388

    Google Scholar 

  • Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK (1987) Piroxicam and 5′-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 32: 89–91

    Google Scholar 

  • Rowland M, Tozer TN (1989) Clinical Pharmacokinetics, concepts and applications. Lea and Febiger, Philadelphia

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University Central Hospital, Turku

    A.-L. Mäkelä

  2. Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland

    K. T. Olkkola & M. J. Mattila

Authors
  1. A.-L. Mäkelä
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. T. Olkkola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. J. Mattila
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mäkelä, AL., Olkkola, K.T. & Mattila, M.J. Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. Eur J Clin Pharmacol 41, 79–81 (1991). https://doi.org/10.1007/BF00280114

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00280114

Key words

Search

Navigation